Market capitalization | $590.28m |
Enterprise Value | $460.54m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 4.70 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-71.77m |
Free Cash Flow (TTM) Free Cash Flow | $-57.69m |
Cash position | $125.03m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
7 Analysts have issued a Oculis forecast:
7 Analysts have issued a Oculis forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.35 -0.35 |
-
|
|
EBITDA | -71 -71 |
-
|
EBIT (Operating Income) EBIT | -72 -72 |
0%
0%
|
Net Profit | -75 -75 |
0%
0%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improve eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.
Head office | Switzerland |
CEO | Riad Sherif |
Employees | 36 |
Founded | 2016 |
Website | oculis.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.